
Annexon, Inc (ANNX) Stock Forecast & Price Target
Annexon, Inc (ANNX) Analyst Ratings
Bulls say
Annexon is well-positioned in the biopharmaceutical industry, with a portfolio of potential blockbuster drugs targeting unmet medical needs in both autoimmune and neurodegenerative diseases. The company's strong leadership, led by CEO Douglas Love, and successful clinical trial results for its lead candidates, Vonaprument and Tinlarebant, indicate a high potential for success in the market. Additionally, the potential for significant sales from these drugs, especially in the under-served market for GA and GBS, is a strong indicator of the company's potential for financial growth.
Bears say
Annexon is a clinical-stage biopharmaceutical company with a pipeline of drug candidates targeting classical complement-mediated disorders, but their lead drug faces competition and may not be as effective as hoped. Investors are also wary of additional capital raises and the long timeline for profitability. There is potential for success in the market, but risks and challenges remain for Annexon.
This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.
Annexon, Inc (ANNX) Analyst Forecast & Price Prediction
Start investing in Annexon, Inc (ANNX)
Order type
Buy in
Order amount
Est. shares
0 shares